Multiple System Atrophy (MSA) Clinical Trials and Treatments

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by degeneration of neurons in the brain regions controlling the autonomic nervous system and movement. The disease presents with combinations of parkinsonian features (rigidity, bradykinesia), cerebellar ataxia (incoordination, gait disturbance), and autonomic failure (orthostatic hypotension, urinary incontinence, sexual dysfunction). Under the microscope, the hallmark is clumps of alpha-synuclein protein inside oligodendrocytes, the support cells that insulate nerve fibers.

The most common symptoms of Multiple System Atrophy include Orthostatic hypotension (dizziness when standing), Parkinsonism or cerebellar ataxia, Vocal tremor and speech difficulty, Erectile dysfunction in men, Incontinence and urinary dysfunction, among others. Multiple System Atrophy affects approximately 2-5 per 100,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Multiple System Atrophy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. MSA research is evaluating neuroprotective therapies, anti-inflammatory agents, and symptom-targeted approaches to slow disease progression. Clinical trials continue testing agents that showed promise in earlier phases.

No drug is FDA approved to slow or stop multiple system atrophy. Northera (droxidopa) is approved for dizziness and lightheadedness on standing in adults with neurogenic orthostatic hypotension, a blood pressure drop on standing, caused by conditions that include multiple system atrophy. Its label says benefit beyond 2 weeks has not been established. Other symptoms such as stiffness, bladder problems and sleep problems are treated with drugs approved for those symptoms in general. The Treatments section of this page lists approved drugs found in FDA labeling data.

The exact cause of Multiple System Atrophy is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Almost always sporadic; SNCA and COQ2 variants only modestly shift risk and there is no diagnostic gene test. The condition affects approximately 2-5 per 100,000 people. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Multiple System Atrophy. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Almost always sporadic; SNCA and COQ2 variants only modestly shift risk and there is no diagnostic gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Multiple System Atrophy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Multiple System Atrophy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.